Hanmi Pharm Co Ltd

KO:128940 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$4.33 Billion
₩6.34 Trillion KRW
Market Cap Rank
#4787 Global
#91 in Korea
Share Price
₩500000.00
Change (1 day)
+0.70%
52-Week Range
₩215000.00 - ₩626000.00
All Time High
₩666173.23
Categories
Companies in Korea Drug Manufacturers - Specialty & Generic
About

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company's products include Gugutams, a urological combination therapy combining two activ… Read more

Hanmi Pharm Co Ltd (128940) - Net Assets

Latest net assets as of September 2025: ₩1.35 Trillion KRW

Based on the latest financial reports, Hanmi Pharm Co Ltd (128940) has net assets worth ₩1.35 Trillion KRW as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩2.04 Trillion) and total liabilities (₩694.79 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets ₩1.35 Trillion
% of Total Assets 65.95%
Annual Growth Rate 10.03%
5-Year Change 49.15%
10-Year Change 66.59%
Growth Volatility 8.39

Hanmi Pharm Co Ltd - Net Assets Trend (2010–2024)

This chart illustrates how Hanmi Pharm Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Hanmi Pharm Co Ltd (2010–2024)

The table below shows the annual net assets of Hanmi Pharm Co Ltd from 2010 to 2024.

Year Net Assets Change
2024-12-31 ₩1.24 Trillion +12.77%
2023-12-31 ₩1.10 Trillion +9.02%
2022-12-31 ₩1.01 Trillion +8.72%
2021-12-31 ₩928.26 Billion +11.58%
2020-12-31 ₩831.89 Billion +1.17%
2019-12-31 ₩822.26 Billion +4.18%
2018-12-31 ₩789.26 Billion -0.40%
2017-12-31 ₩792.42 Billion +7.88%
2016-12-31 ₩734.52 Billion -1.38%
2015-12-31 ₩744.81 Billion +26.40%
2014-12-31 ₩589.25 Billion +27.29%
2013-12-31 ₩462.92 Billion +13.09%
2012-12-31 ₩409.34 Billion +8.23%
2011-12-31 ₩378.22 Billion +16.24%
2010-12-31 ₩325.38 Billion --

Equity Component Analysis

This analysis shows how different components contribute to Hanmi Pharm Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 68088799061000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings ₩680.89 Billion 62.76%
Other Components ₩404.01 Billion 37.24%
Total Equity ₩1.08 Trillion 100.00%

Hanmi Pharm Co Ltd Competitors by Market Cap

The table below lists competitors of Hanmi Pharm Co Ltd ranked by their market capitalization.

Company Market Cap
SDIC Essence Holdings Co Ltd
SHG:600061
 		$2.13 Billion
Wuxi Taclink Optoelectronics Technology Co. Ltd. A
SHG:688205
 		$2.13 Billion
Fujian Newland Computer Co Ltd
SHE:000997
 		$2.13 Billion
Wihlborgs Fastigheter AB
ST:WIHL
 		$2.13 Billion
Sankyu Inc
F:SNK
 		$2.13 Billion
Capri Holdings Ltd
NYSE:CPRI
 		$2.13 Billion
UNO Minda Limited
NSE:UNOMINDA
 		$2.13 Billion
WOOLWORTHS HDGS GDR
F:WN30
 		$2.13 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Hanmi Pharm Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 955,442,389,530 to 1,084,893,341,850, a change of 129,450,952,320 (13.5%).
  • Net income of 121,315,102,380 contributed positively to equity growth.
  • Dividend payments of 12,555,417,680 reduced retained earnings.
  • Share repurchases of 3,280,080,960 reduced equity.
  • Other factors increased equity by 23,971,348,580.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income ₩121.32 Billion +11.18%
Dividends Paid ₩12.56 Billion -1.16%
Share Repurchases ₩3.28 Billion -0.3%
Other Changes ₩23.97 Billion +2.21%
Total Change ₩- 13.55%

Book Value vs Market Value Analysis

This analysis compares Hanmi Pharm Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 5.84x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 8.28x to 5.84x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2017-12-31 ₩60354.92 ₩500000.00 x
2018-12-31 ₩59685.60 ₩500000.00 x
2019-12-31 ₩61478.56 ₩500000.00 x
2020-12-31 ₩62059.72 ₩500000.00 x
2021-12-31 ₩65610.38 ₩500000.00 x
2022-12-31 ₩70009.40 ₩500000.00 x
2023-12-31 ₩75287.84 ₩500000.00 x
2024-12-31 ₩85557.97 ₩500000.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Hanmi Pharm Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 11.18%
  • The company shows good efficiency in utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 8.11%
  • • Asset Turnover: 0.74x
  • • Equity Multiplier: 1.86x
  • Recent ROE (11.18%) is above the historical average (8.27%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2011 0.38% 0.21% 0.77x 2.34x ₩-32.34 Billion
2012 6.25% 3.36% 0.81x 2.31x ₩-13.61 Billion
2013 10.73% 6.02% 0.83x 2.15x ₩2.99 Billion
2014 6.73% 4.66% 0.74x 1.96x ₩-17.24 Billion
2015 22.88% 11.72% 0.76x 2.55x ₩86.95 Billion
2016 3.54% 2.64% 0.55x 2.42x ₩-42.62 Billion
2017 8.49% 6.59% 0.55x 2.33x ₩-10.74 Billion
2018 3.54% 2.45% 0.60x 2.40x ₩-45.43 Billion
2019 7.20% 4.68% 0.58x 2.64x ₩-20.27 Billion
2020 1.64% 1.11% 0.57x 2.58x ₩-61.04 Billion
2021 8.35% 5.57% 0.62x 2.41x ₩-13.27 Billion
2022 9.50% 6.22% 0.69x 2.21x ₩-4.39 Billion
2023 15.31% 9.81% 0.79x 1.99x ₩50.69 Billion
2024 11.18% 8.11% 0.74x 1.86x ₩12.83 Billion

Industry Comparison

This section compares Hanmi Pharm Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $472,965,132,317
  • Average return on equity (ROE) among peers: 3.29%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Hanmi Pharm Co Ltd (128940) ₩1.35 Trillion 0.38% 0.52x $2.13 Billion
Dongwha Pharm.Co.Ltd (000020) $300.87 Billion 3.12% 0.25x $76.07 Million
Yuhan Corp Preferred (000105) $2.15 Trillion 3.29% 0.37x $3.71 Billion
Yuyu Pharma (000220) $120.36 Billion -5.97% 0.65x $29.69 Million
Ildong Holdings Co Ltd (000230) $310.17 Billion 8.80% 0.65x $48.77 Million
Samil Pharm (000520) $66.60 Billion 0.00% 0.82x $103.58 Million
Donga Socio Holdings (000640) $1.03 Trillion 5.64% 0.91x $204.37 Million
Jw Pharmac (001060) $265.44 Billion 13.94% 1.43x $278.79 Million
JW Pharmaceutical Corp (001065) $276.31 Billion -3.96% 1.36x $246.19 Million
Samsung Pharm (001360) $46.24 Billion -2.15% 1.82x $64.85 Million
Ahn-Gook Pharmaceutical Co. Ltd (001540) $165.68 Billion 10.17% 0.83x $27.46 Million